Vitamin K1-containing urea skin cream

Drug Overview

Vitamin K1-containing urea skin cream is a specialized topical therapeutic designed to manage and prevent dermatological toxicities caused by certain cancer treatments. It is primarily used for patients receiving Epidermal Growth Factor Receptor (EGFR) inhibitors (e.g., cetuximab, erlotinib) and VEGFR inhibitors.

In the clinical landscape of March 2026, this cream is recognized as a vital supportive care agent. Systemic cancer drugs often inadvertently block growth signals in the skin, leading to painful, acne-like rashes and cracks. This cream provides a localized source of vitamin K1 to “re-activate” these signals in the skin cells without interfering with the drug’s ability to kill tumor cells elsewhere in the body.

Generic Name: Vitamin K1-containing urea skin cream.
Most Common Formulation: Reconval K1 (0.1% Vitamin K1 + Urea).
Drug Class: Supportive Care; Topical Passive Immunotherapeutic.
Target Population: Oncology patients experiencing acneiform eruptions, severe xerosis (dryness), or painful skin fissures (rhagades).
FDA Approval Status: Individual Ingredients Approved; Combination Investigational. While Vitamin K1 (Phytonadione) and Urea are both FDA-approved for various uses, the specific combination as a “cancer drug” for skin rash is generally classified as an investigational supportive care product or a medical device in the U.S. and EU. It is not currently approved as a primary “drug” for the treatment of cancer itself.

What Is It and How Does It Work? (Mechanism of Action)

The cream functions as a biological “rescue” therapy for the skin’s barrier, which is often severely compromised by targeted oncology agents.

Vitamin K1 (Phytonadione): Acts as a cofactor that can locally stimulate the EGFR pathway. By providing the skin with K1, the cream helps cells maintain their integrity and repair mechanisms even in the presence of systemic inhibitors.
Urea: A potent humectant and keratolytic. It pulls moisture into the deep layers of the skin and softens hardened, scaly patches, allowing the vitamin K1 to penetrate more effectively.

Targeting the CD20 Receptor

Clarification: Vitamin K1-containing urea cream does not target the CD20 receptor. Therapies targeting CD20 are typically systemic monoclonal antibodies used for B-cell malignancies or autoimmune diseases. This cream’s mechanism of action is strictly localized to stimulating the EGFR pathway in epidermal cells.

FDA-Approved Clinical Indications

The regulatory pathway for this cream differs from primary cancer drugs, as it manages side effects rather than treating the underlying malignancy.

Vitamin K1: FDA-approved for nutritional deficiency and blood clotting.
Urea: FDA-approved for dry skin (Xerosis) and hyperkeratotic conditions.

Oncological Uses (Investigational)

As of March 2026, the specific combination of vitamin K1 and urea for managing EGFR/VEGFR-inhibitor-induced skin rash is classified as an investigational supportive care product or Class I medical device in the U.S. and EU. Many oncologists prescribe it off-label based on strong clinical trial evidence to improve patient tolerance to primary cancer treatments.

Non-oncological Uses

Separately, the ingredients are widely used in general dermatology and medicine. Urea is a standard treatment for severe calluses and dry skin, while systemic Vitamin K1 is used to reverse anticoagulant toxicity.

Dosage and Administration Protocols

Because this is a topical agent, “dosage” refers to application technique rather than systemic weight-based metrics.

Prophylactic (Prevention): Start applying on the first day of cancer therapy, prior to the appearance of any rash.
Standard Treatment: Apply to the affected areas twice daily.
Target Areas: Head, neck, trunk, and extremities where rashes or fissures typically emerge.
Technique: Cleanse the area with lukewarm water, pat dry with a soft towel, and gently massage a thin layer until fully absorbed.

Dose Adjustments

Systemic dose adjustments are not necessary due to negligible absorption. However, application frequency can be adjusted (applied several times a day) as needed for comfort or to manage extreme dryness.

Clinical Efficacy and Research Results

Clinical validation from recent trials (such as the EVITA post-hoc analysis) has established the cream’s efficacy in modern oncology:

Rash Reduction: Twice-daily application shows a median improvement of 8 days and significant down-staging of rashes within 18 days.
Maintenance of Therapy: By preventing severe (Grade 3/4) rashes, the cream helps patients avoid dose reductions or interruptions of their life-saving targeted therapies.
Fissure Management: Marked reduction in painful skin cracks on fingertips and soles compared to standard moisturizers.

Multiple Sclerosis (ULTIMATE I & II Trials)

Clarification: The ULTIMATE trials evaluated a systemic anti-CD20 therapy (ublituximab) for Multiple Sclerosis. Vitamin K1 cream is not used or researched for Multiple Sclerosis. Its primary clinical data relies on oncology dermatological trials like the EVITA studies.

Leukemia Research Data

Clarification: This cream has no direct anti-leukemic properties and is not researched as a primary leukemia treatment. It is strictly a topical supportive agent for targeted therapy side effects.

Safety Profile and Side Effects

The cream is exceptionally well-tolerated because it acts locally without interfering with the efficacy of the primary cancer treatment.

Black Box Warning

Clarification: There is no Black Box Warning for Vitamin K1-containing urea skin cream.

Common Side Effects (>10%)

Mild, localized tingling upon application.
Temporary, localized redness at the application site.

Serious Adverse Events

No common systemic risks or serious adverse events have been reported as of 2026 due to the negligible systemic absorption of the product.

Management Strategies

Discontinue use if a known allergy or hypersensitivity reaction occurs.
Contraindicated for patients with known allergies to Vitamin K1, Soybean Oil (often used as a carrier), or parabens.

Research Areas

Ongoing research in the 2024–2026 period focuses heavily on post-hoc analyses of dermo-cosmetic supportive care to establish standardized global guidelines for prophylactic skin management in targeted oncology.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

No specific bloodwork or systemic pre-treatment tests are required. A simple review of the patient’s allergy history (specifically regarding parabens, soy, or phytonadione) is sufficient.

Precautions During Treatment

Ensure the product being used is an oncology-grade formulation (like Reconval K1) and not a general cosmetic vitamin K cream meant for under-eye dark circles or simple bruising, as formulations vary drastically.

“Do’s and Don’ts” List

Do start applying the cream proactively on day one of your cancer treatment.
Do gently pat the skin dry before application; avoid rubbing.
Do communicate with your oncology team if your skin toxicity worsens.

Don’t use if you have an allergy to soybean oil, parabens, or Vitamin K1.
Don’t substitute this specific formulation with standard cosmetic creams without consulting your care team.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Vitamin K1-containing urea skin cream is a supportive care product. Always consult with your oncologist or dermatology nurse before starting new skin treatments during cancer therapy.